Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modeling in Therapy01:26

Modeling in Therapy

715
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
715
Models of Health Promotion and Illness Prevention II01:18

Models of Health Promotion and Illness Prevention II

2.3K
The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results...
2.3K
Clearance Models: Noncompartmental Models01:17

Clearance Models: Noncompartmental Models

346
Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. However, a noncompartmental model offers an alternative method for assessing clearance, primarily employing empirical data obtained after administering a single drug dose.
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...
346
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
Autoimmune Disorders01:29

Autoimmune Disorders

2.2K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.2K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

500
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
500

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulation-based assessment of a Bayesian M-spline survival model with flexible baseline hazard and time-dependent effects.

BMC medical research methodology·2026
Same author

Optimal risk-assessment scheduling for primary prevention of cardiovascular disease.

Journal of the Royal Statistical Society. Series A, (Statistics in Society)·2025
Same author

Unanchored simulated treatment comparison on survival outcomes using parametric and Royston-Parmar models with application to lenvatinib plus pembrolizumab in renal cell carcinoma.

BMC medical research methodology·2025
Same author

Protection of vaccine boosters and prior infection against mild/asymptomatic and moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October 2023 to March 2024.

The Journal of infection·2024
Same author

Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort.

The Lancet regional health. Europe·2023
Same author

survextrap: a package for flexible and transparent survival extrapolation.

BMC medical research methodology·2023
Same journal

Associations Between Social Risk Factors and Acute Care Use Among Patients with Rheumatic Conditions.

Arthritis care & research·2026
Same journal

Engagement Patterns with an AI Health Coach for Systemic Sclerosis Self-Management: A Mixed Methods Study.

Arthritis care & research·2026
Same journal

Anorectal Dysfunction in Systemic Sclerosis: Clinical Phenotypes and Functional Patterns.

Arthritis care & research·2026
Same journal

Determinants of body mass index in early systemic sclerosis: implications for nutritional risk stratification.

Arthritis care & research·2026
Same journal

Frailty Predicts Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis.

Arthritis care & research·2026
Same journal

Assessing Reliability of an Electronic Gout Flare Assessment Protocol.

Arthritis care & research·2026
See all related articles

Related Experiment Video

Updated: Apr 4, 2026

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.2K

On Modelling Minimal Disease Activity.

Christopher H Jackson1, Li Su1, Dafna D Gladman2

  • 1MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge University, Cambridge, UK.

Arthritis Care & Research
|August 29, 2015
PubMed
Summary
This summary is machine-generated.

Statistical modeling of minimal disease activity (MDA) using intermittent clinic data is explored. Hidden model methodology offers more precise estimates of MDA duration and probability compared to complete case analysis, reducing bias.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Related Experiment Videos

Last Updated: Apr 4, 2026

Minimal Erythema Dose MED Testing
06:24

Minimal Erythema Dose MED Testing

Published on: May 28, 2013

43.2K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.7K

Area of Science:

  • Rheumatology
  • Biostatistics
  • Clinical Research

Background:

  • Assessing minimal disease activity (MDA) in psoriatic arthritis is crucial for treatment monitoring.
  • Intermittent clinic visits present challenges for accurate MDA status determination.
  • Existing statistical methods may not fully utilize available patient data.

Purpose of the Study:

  • To develop and evaluate statistical modeling methods for minimal disease activity (MDA) using data from infrequent clinic visits.
  • To compare the performance of complete case analysis versus hidden model methodology in estimating MDA parameters.
  • To assess the impact of incorporating data from visits with incomplete MDA information.

Main Methods:

  • Employed a 2-state statistical model for analyzing MDA.
  • Compared "complete case" analysis (using only visits with known MDA status) with hidden model methodology.
  • Utilized data from an observational psoriatic arthritis cohort, including 856 patients and 7,024 clinic visits.

Main Results:

  • Analysis incorporated data from nearly all clinic visits, though only 62.6% had complete MDA information.
  • Hidden 2-state model analysis yielded smaller estimates for mean MDA episode duration (3.10 years) compared to complete case analysis (4.18 years).
  • The hidden model also estimated longer expected times spent in MDA (>1 year) and higher probabilities (0.91) over 10 years.

Conclusions:

  • A 2-state model is effective for analyzing minimal disease activity (MDA).
  • Incorporating data from visits with undetermined MDA status enhances analytical precision.
  • Complete case analyses risk bias and loss of precision; hidden models offer a more robust approach.